<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36708022</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev Med Virol</ISOAbbreviation></Journal><ArticleTitle>Inflammatory and vascular biomarkers in post-COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers.</ArticleTitle><Pagination><StartPage>e2424</StartPage><MedlinePgn>e2424</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.2424</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 may inflict a post-viral condition known as post-COVID-19 syndrome (PCS) or long-COVID. Studies measuring levels of inflammatory and vascular biomarkers in blood, serum, or plasma of COVID-19 survivors with PCS versus non-PCS controls have produced mixed findings. Our review sought to meta-analyse those studies. A systematic literature search was performed across five databases until 25 June 2022, with an updated search on 1 November 2022. Data analyses were performed with Review Manager and R Studio statistical software. Twenty-four biomarkers from 23 studies were meta-analysed. Higher levels of C-reactive protein (Standardized mean difference (SMD)&#xa0;=&#xa0;0.20; 95% CI: 0.02-0.39), D-dimer (SMD&#xa0;=&#xa0;0.27; 95% CI: 0.09-0.46), lactate dehydrogenase (SMD&#xa0;=&#xa0;0.30; 95% CI: 0.05-0.54), and leukocytes (SMD&#xa0;=&#xa0;0.34; 95% CI: 0.02-0.66) were found in COVID-19 survivors with PCS than in those without PCS. After sensitivity analyses, lymphocytes (SMD&#xa0;=&#xa0;0.30; 95% CI: 0.12-0.48) and interleukin-6 (SMD&#xa0;=&#xa0;0.30; 95% CI: 0.12-0.49) were also significantly higher in PCS than non-PCS cases. No significant differences were noted in the remaining biomarkers investigated (e.g., ferritin, platelets, troponin, and fibrinogen). Subgroup analyses suggested the biomarker changes were mainly driven by PCS cases diagnosed via manifestation of organ abnormalities rather than symptomatic persistence, as well as PCS cases with duration of &lt;6 than &#x2265;6&#xa0;months. In conclusion, our review pinpointed certain inflammatory and vascular biomarkers associated with PCS, which may shed light on potential new approaches to understanding, diagnosing, and treating PCS.</AbstractText><CopyrightInformation>&#xa9; 2023 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yong</LastName><ForeName>Shin Jie</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-9752-8386</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halim</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halim</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, School of Science, Engineering and Environment, University of Salford, Greater Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shiliang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Surveillance and Applied Research, Public Health Agency of Canada, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aljeldah</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Shammari</LastName><ForeName>Basim R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwarthan</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhajri</LastName><ForeName>Mashael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alawfi</LastName><ForeName>Abdulsalam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, College of Medicine, Taibah University, Al-Madinah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshengeti</LastName><ForeName>Amer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, College of Medicine, Taibah University, Al-Madinah, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection Prevention and Control, Prince Mohammad Bin Abdulaziz Hospital, National Guard Health Affairs, Al-Madinah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khamis</LastName><ForeName>Faryal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infection Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsalman</LastName><ForeName>Jameela</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infection Disease Unit, Department of Internal Medicine, Salmaniya Medical Complex, Ministry of Health, Manama, Bahrain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshukairi</LastName><ForeName>Abeer N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abukhamis</LastName><ForeName>Nujoud A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Molecular Virology Laboratory, East Jeddah Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almaghrabi</LastName><ForeName>Fatimah S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Molecular Virology Laboratory, East Jeddah Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almuthree</LastName><ForeName>Souad A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, King Abdullah Medical City, Makkah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsulaiman</LastName><ForeName>Abdulrahman M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Laboratory Department, Almostaqbal Medical Laboratories, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshehail</LastName><ForeName>Bashayer M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0003-2372-9462</Identifier><AffiliationInfo><Affiliation>Pharmacy Practice Department, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaraj</LastName><ForeName>Amal H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Pediatric Department, Abqaiq General Hospital, First Eastern Health Cluster, Abqaiq, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhawaj</LastName><ForeName>Shorouq A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Nursing Model of Care, Nephrology Dialysis &amp; Transplant Unit, Qatif Central Hospital, Qatif, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohapatra</LastName><ForeName>Ranjan K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Government College of Engineering, Keonjhar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabaan</LastName><ForeName>Ali A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-6774-9847</Identifier><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">vascular disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>28</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36708022</ArticleId><ArticleId IdType="doi">10.1002/rmv.2424</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154. https://doi.org/10.1038/s41579-020-00459-7</Citation></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. https://doi.org/10.1136/bmj.n136</Citation></Reference><Reference><Citation>Siso-Almirall A, Brito-Zeron P, Conangla Ferrin L, et&#xa0;al. Long covid-19: proposed primary care clinical guidelines for diagnosis and disease management. Int J Environ Res Public Health. 2021;18(8):4350. https://doi.org/10.3390/ijerph18084350</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. https://doi.org/10.1136/bmj.n1648</Citation></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et&#xa0;al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427. https://doi.org/10.1136/bmjgh-2021-005427</Citation></Reference><Reference><Citation>Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2021;32(4):e2315. https://doi.org/10.1002/rmv.2315</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et&#xa0;al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. https://doi.org/10.1038/s41591-021-01283-z</Citation></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Inf Disp. 2021;53(10):737-754. https://doi.org/10.1080/23744235.2021.1924397</Citation></Reference><Reference><Citation>Yong SJ. Persistent brainstem dysfunction in long-COVID: a hypothesis. ACS Chem Neurosci. 2021;12(4):573-580. https://doi.org/10.1021/acschemneuro.0c00793</Citation></Reference><Reference><Citation>Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18(9):666-682. https://doi.org/10.1038/s41569-021-00552-1</Citation></Reference><Reference><Citation>Dal Lin C, Tona F, Osto E. The crosstalk between the cardiovascular and the immune system. Vasc Biol. 2019;1(1):H83-H88. https://doi.org/10.1530/VB-19-0023</Citation></Reference><Reference><Citation>Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479(4):537-559. https://doi.org/10.1042/BCJ20220016</Citation></Reference><Reference><Citation>Ahamed J, Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest. 2022;132(15):132. https://doi.org/10.1172/JCI161167</Citation></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https://doi.org/10.1186/1471-2288-14-135</Citation></Reference><Reference><Citation>Wells G, Shea D, O'Connell D, et&#xa0;al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Accessed 5 June 2022. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</Citation></Reference><Reference><Citation>Takeshima N, Sozu T, Tajika A, Ogawa Y, Hayasaka Y, Furukawa TA. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? BMC Med Res Methodol. 2014;14(1):30. https://doi.org/10.1186/1471-2288-14-30</Citation></Reference><Reference><Citation>Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat. 2005;30(3):261-293. https://doi.org/10.3102/10769986030003261</Citation></Reference><Reference><Citation>Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T. 2008;33(12):700-711.</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. https://doi.org/10.1002/sim.1186</Citation></Reference><Reference><Citation>Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193-206. https://doi.org/10.1037/1082-989X.11.2.193</Citation></Reference><Reference><Citation>Fletcher J. What is heterogeneity and is it important? BMJ. 2007;334(7584):94-96. https://doi.org/10.1136/bmj.39057.406644.68</Citation></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ Clin Res. 1997;315(7109):629-634. https://doi.org/10.1136/bmj.315.7109.629</Citation></Reference><Reference><Citation>Haffke M, Freitag H, Rudolf G, et&#xa0;al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. 2022;20(1):138. https://doi.org/10.1186/s12967-022-03346-2</Citation></Reference><Reference><Citation>Sasso EM, Muraki K, Eaton-Fitch N, et&#xa0;al. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. Mol Med. 2022;28(1):98. https://doi.org/10.1186/s10020-022-00528-y</Citation></Reference><Reference><Citation>Aparisi A, Ybarra-Falcon C, Garcia-Gomez M, et&#xa0;al. Exercise ventilatory inefficiency in post-COVID-19 syndrome: insights from a prospective evaluation. J Clin Med. 2021;10(12):2591. https://doi.org/10.3390/jcm10122591</Citation></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, et&#xa0;al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13(1):446. https://doi.org/10.1038/s41467-021-27797-1</Citation></Reference><Reference><Citation>Correa HL, Deus LA, Araujo TB, et&#xa0;al. Phosphate and IL-10 concentration as predictors of long-covid in hemodialysis patients: a Brazilian study. Front Immunol. 2022;13:1006076. https://doi.org/10.3389/fimmu.2022.1006076</Citation></Reference><Reference><Citation>Diaz-Salazar S, Navas R, Sainz-Maza L, et&#xa0;al. Blood group O is associated with post-COVID-19 syndrome in outpatients with a low comorbidity index. Inf Disp. 2022;54(12):897-908. https://doi.org/10.1080/23744235.2022.2115548</Citation></Reference><Reference><Citation>Di Gennaro L, Valentini P, Sorrentino S, et&#xa0;al. Extended coagulation profile of children with Long Covid: a prospective study. Sci Rep. 2022;12(1):18392. https://doi.org/10.1038/s41598-022-23168-y</Citation></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Kelly JD, et&#xa0;al. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight. 2022;7(10):e157053. https://doi.org/10.1172/jci.insight.157053</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Ryan-Murua P, Rodr&#xed;guez-Jim&#xe9;nez J, Palacios-Ce&#xf1;a M, Arendt-Nielsen L, Torres-Macho J. Serological biomarkers at hospital admission are not related to long-term post-COVID fatigue and dyspnea in COVID-19 survivors. Respiration. 2022;101(7):1-8. https://doi.org/10.1159/000524042</Citation></Reference><Reference><Citation>Garcia-Abellan J, Fernandez M, Padilla S, et&#xa0;al. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. 2022;13:920627. https://doi.org/10.3389/fimmu.2022.920627</Citation></Reference><Reference><Citation>Garcia-Hidalgo MC, Pelaez R, Gonzalez J, et&#xa0;al. Genome-wide transcriptional profiling of pulmonary functional sequelae in ARDS- secondary to SARS-CoV-2 infection. Biomed Pharmacother. 2022;154:113617. https://doi.org/10.1016/j.biopha.2022.113617</Citation></Reference><Reference><Citation>Kerget B, Celik E, Kerget F, et&#xa0;al. Evaluation of 3-month follow-up of patients with postacute COVID-19 syndrome. J Med Virol. 2022;94(5):2026-2034. https://doi.org/10.1002/jmv.27579</Citation></Reference><Reference><Citation>Maamar M, Artime A, Pariente E, et&#xa0;al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. 2022;38(6):1-9. https://doi.org/10.1080/03007995.2022.2042991</Citation></Reference><Reference><Citation>Nunez-Fernandez M, Ramos-Hernandez C, Garcia-Rio F, et&#xa0;al. Alterations in respiratory function test three months after hospitalisation for COVID-19 pneumonia: value of determining Nitric Oxide diffusion. J Clin Med. 2021;10(10):10. https://doi.org/10.3390/jcm10102119</Citation></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et&#xa0;al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224(11):1839-1848. https://doi.org/10.1093/infdis/jiab490</Citation></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et&#xa0;al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210-216. https://doi.org/10.1038/s41590-021-01113-x</Citation></Reference><Reference><Citation>Sibila O, Perea L, Albacar N, et&#xa0;al. Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. Respir Res. 2022;23(1):37. https://doi.org/10.1186/s12931-022-01955-5</Citation></Reference><Reference><Citation>Stavileci B, Ozdemir E, Ozdemir B, Ereren E, Cengiz M. De-novo development of fragmented QRS during a six-month follow-up period in patients with COVID-19 disease and its cardiac effects. J Electrocardiol. 2022;72:44-48. https://doi.org/10.1016/j.jelectrocard.2022.02.012</Citation></Reference><Reference><Citation>Wallis TJM, Heiden E, Horno J, et&#xa0;al. Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. Article. Respir Res. 2021;22(1):157. https://doi.org/10.1186/s12931-021-01750-8</Citation></Reference><Reference><Citation>Wu J, Tang L, Ma Y, et&#xa0;al. Immunological profiling of COVID-19 patients with pulmonary sequelae. mBio. 2021;12(5):e0159921. https://doi.org/10.1128/mBio.01599-21</Citation></Reference><Reference><Citation>Wu XY, Deng KQ, Li CZ, et&#xa0;al. Cardiac involvement in recovered patients from COVID-19: a preliminary 6-month follow-up study. Front Cardiovasc Med. 2021;8:8654405. https://doi.org/10.3389/fcvm.2021.654405</Citation></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, et&#xa0;al. Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. 2022;225(12):2155-2162. https://doi.org/10.1093/infdis/jiac017</Citation></Reference><Reference><Citation>Flaskamp L, Roubal C, Uddin S, et&#xa0;al. Serum of post-COVID-19 syndrome patients with or without ME/CFS differentially affects endothelial cell function in vitro. Cells. 2022;11(15):2376. https://doi.org/10.3390/cells11152376</Citation></Reference><Reference><Citation>Kruger A, Vlok M, Turner S, et&#xa0;al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21(1):190. https://doi.org/10.1186/s12933-022-01623-4</Citation></Reference><Reference><Citation>Patel MA, Knauer MJ, Nicholson M, et&#xa0;al. Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med. 2022;28(1):122. https://doi.org/10.1186/s10020-022-00548-8</Citation></Reference><Reference><Citation>Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. https://doi.org/10.3389/fimmu.2018.00754</Citation></Reference><Reference><Citation>Bounds EJ, Kok SJD. Dimer. StatPearls; 2022.</Citation></Reference><Reference><Citation>Farhana A, Lappin SL. Biochemistry, lactate dehydrogenase. StatPearls. 2022.</Citation></Reference><Reference><Citation>Tvedten H, Raskin RE. Leukocyte disorders. Small Anim Clin Diagn by Lab Methods. 2012:63-91. https://doi.org/10.1016/b978-1-4377-0657-4.00004-1</Citation></Reference><Reference><Citation>Mank V, Brown K. Leukocytosis. StatPearls; 2022.</Citation></Reference><Reference><Citation>Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. https://doi.org/10.1101/cshperspect.a016295</Citation></Reference><Reference><Citation>Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22(3):147-151. https://doi.org/10.1097/CRD.0000000000000021</Citation></Reference><Reference><Citation>Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8(1):37. https://doi.org/10.1186/s40364-020-00217-0</Citation></Reference><Reference><Citation>Malik P, Patel U, Mehta D, et&#xa0;al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107-108. https://doi.org/10.1136/bmjebm-2020-111536</Citation></Reference><Reference><Citation>King LS. Signs and symptoms. JAMA. 1968;206(5):1063-1065. https://doi.org/10.1001/jama.206.5.1063</Citation></Reference><Reference><Citation>Rosendal M, Jarbol DE, Pedersen AF, Andersen RS. Multiple perspectives on symptom interpretation in primary care research. BMC Fam Pract. 2013;14(1):167. https://doi.org/10.1186/1471-2296-14-167</Citation></Reference><Reference><Citation>Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur J Pediatr. 2022;181(4):1597-1607. https://doi.org/10.1007/s00431-021-04345-z</Citation></Reference><Reference><Citation>Helmsdal G, Hanusson KD, Kristiansen MF, et&#xa0;al. Long COVID in the long run-23-month follow-up study of persistent symptoms. Open Forum Infect Dis. 2022;9(7):ofac270. https://doi.org/10.1093/ofid/ofac270</Citation></Reference><Reference><Citation>Wynberg E, van Willigen HDG, Dijkstra M, et&#xa0;al. Evolution of coronavirus disease 2019 (COVID-19) symptoms during the first 12 Months after illness onset. Clin Infect Dis. 2022;75(1):e482-e490. https://doi.org/10.1093/cid/ciab759</Citation></Reference><Reference><Citation>Righi E, Mirandola M, Mazzaferri F, et&#xa0;al. Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: a prospective cohort study. J Infect. 2022;84(4):566-572. https://doi.org/10.1016/j.jinf.2022.02.003</Citation></Reference><Reference><Citation>Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010;1800(8):760-769. https://doi.org/10.1016/j.bbagen.2010.03.011</Citation></Reference><Reference><Citation>Justiz Vaillant AA, Zito PM. Neutropenia. StatPearls; 2022.</Citation></Reference><Reference><Citation>Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol. 2018;9:113. https://doi.org/10.3389/fphys.2018.00113</Citation></Reference><Reference><Citation>Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 1998;9(1):9-23. https://doi.org/10.1016/s1359-6101(97)00022-1</Citation></Reference><Reference><Citation>Gschwandtner M, Derler R, Midwood KS. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol. 2019;10:2759. https://doi.org/10.3389/fimmu.2019.02759</Citation></Reference><Reference><Citation>Islam H, Chamberlain TC, Mui AL, Little JP. Elevated interleukin-10 levels in COVID-19: potentiation of pro-inflammatory responses or impaired anti-inflammatory action? Front Immunol. 2021;12:677008. https://doi.org/10.3389/fimmu.2021.677008</Citation></Reference><Reference><Citation>Fan BE, Wong SW, Sum CLL, et&#xa0;al. Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: assessing the long-term outcomes in COVID-19 patients. Am J Hematol. 2022;97(7):915-923. https://doi.org/10.1002/ajh.26575</Citation></Reference><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, et&#xa0;al. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Letter. Blood Adv. 2021;5(3):756-759. https://doi.org/10.1182/bloodadvances.2020003968</Citation></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, et&#xa0;al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. https://doi.org/10.1186/s12933-021-01359-7</Citation></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, et&#xa0;al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021;19(10):2546-2553. https://doi.org/10.1111/jth.15490</Citation></Reference><Reference><Citation>Custodero C, Ciavarella A, Panza F, et&#xa0;al. Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. Geroscience. 2022;44(3):1373-1392. https://doi.org/10.1007/s11357-022-00556-w</Citation></Reference><Reference><Citation>Goncharov NV, Popova PI, Avdonin PP, et&#xa0;al. Markers of endothelial cells in normal and pathological conditions. Biochem (Mosc) Suppl Ser A Membr Cell Biol. 2020;14(3):167-183. https://doi.org/10.1134/S1990747819030140</Citation></Reference><Reference><Citation>Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(19):12422. https://doi.org/10.3390/ijerph191912422</Citation></Reference><Reference><Citation>Yong SJ, Halim A, Halim M, et&#xa0;al. Rare adverse events associated with BNT162b2 mRNA vaccine (Pfizer-BioNTech): a review of large-scale, controlled surveillance studies. Vaccines (Basel). 2022;10(7):1067. https://doi.org/10.3390/vaccines10071067</Citation></Reference><Reference><Citation>Alhumaid S, Al Mutair A, Rabaan AA, et&#xa0;al. New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review. BMC Gastroenterol. 2022;22(1):433. https://doi.org/10.1186/s12876-022-02507-3</Citation></Reference><Reference><Citation>Alhumaid S, Rabaan AA, Dhama K, et&#xa0;al. Solid organ rejection following SARS-CoV-2 vaccination or COVID-19 infection: a systematic review and meta-analysis. Vaccines (Basel). 2022;10(8):1289. https://doi.org/10.3390/vaccines10081289</Citation></Reference><Reference><Citation>Funk PR, Yogurtcu ON, Forshee RA, Anderson SA, Marks PW, Yang H. Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years. Vaccine. 2022;40(19):2781-2789. https://doi.org/10.1016/j.vaccine.2022.03.030</Citation></Reference><Reference><Citation>Gurdasani D, Bhatt S, Costello A, et&#xa0;al. Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis. J R Soc Med. 2021;114(11):513-524. https://doi.org/10.1177/01410768211052589</Citation></Reference><Reference><Citation>Oudkerk M, Buller HR, Kuijpers D, et&#xa0;al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the national institute for public health of The Netherlands. Radiology. 2020;297(1):E216-E222. https://doi.org/10.1148/radiol.2020201629</Citation></Reference><Reference><Citation>Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744. https://doi.org/10.3389/fimmu.2019.01744</Citation></Reference><Reference><Citation>Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006;24(1):33-50. https://doi.org/10.1111/j.1527-3466.2006.00033.x</Citation></Reference><Reference><Citation>Gordon AC, Mouncey PR, Al-Beidh F, et&#xa0;al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med. 2021;384(16):1491-1502. https://doi.org/10.1056/NEJMoa2100433</Citation></Reference><Reference><Citation>Miyashita N, Kawai Y, Inamura N, et&#xa0;al. Setting a standard for the&#xa0;initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2015;21(3):153-160. https://doi.org/10.1016/j.jiac.2014.10.008</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>